Kratom safety and toxicology in the public health context: research needs to better inform regulation
Frontiers in Pharmacology · 03.06.2024 · 15
DOI: 10.3389/fphar.2024.1403140 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Frontiers in Pharmacology, online erschienen am 03.06.2024. Verfasst von Jack E Henningfield und 3 weiteren Autor:innen. Beteiligte Einrichtung: Pinney Associates, Inc., Bethesda, MD, United States. Die Arbeit wurde bisher 49-mal zitiert (Crossref) und nennt 165 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Although kratom use has been part of life for centuries in Southeast Asia, the availability and use of kratom in the United States (US) increased substantially since the early 2000s when there was little information on kratom pharmacology, use patterns, and effects, all critical to guiding regulation and policy. Here we provide a synthesis of research with several hundred English-language papers published in the past 5 years drawing from basic research, epidemiological and surveillance data, and recent clinical research. This review of available literature aims to provide an integrated update regarding our current understanding of kratom’s benefits, risks, pharmacology, and epidemiology, which may inform United States-based kratom regulation. Recent surveillance indicates there are likely several million past-year kratom consumers, though estimates vary widely. Even without precise prevalence data, kratom use is no longer a niche, with millions of United States adults using it for myriad reasons. Despite its botanical origins in the coffee tree family and its polypharmacy, kratom is popularly characterized as an opioid with presumed opioid-system-based risks for addiction or overdose. Neuropharmacology, toxicology, and epidemiology studies show that kratom is more accurately characterized as a substance with diverse and complex pharmacology. Taken together the work reviewed here provides a foundation for future scientific studies, as well as a guide for ongoing efforts to regulate kratom. This work also informs much-needed federal oversight, including by the United States Food and Drug Administration. We conclude with recommendations for kratom regulation and research priorities needed to address current policy and knowledge gaps around this increasingly used botanical product.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Pinney Associates, Inc., Bethesda, MD, United States.
- Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Bethesda, MD, United States.
- College of Pharmacy, Department of Medicinal Chemistry, University of Florida, Gainesville, FL, United States.
- Institute of Emerging Health Professions, Thomas Jefferson University, Philadelphia, PA, United States.
- Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, MD, United States.
Zitieren
APA
Henningfield, J. E., Grundmann, O., Huestis, M. A., & Smith, K. E. (2024). Kratom safety and toxicology in the public health context: research needs to better inform regulation. Frontiers in Pharmacology, 15. https://doi.org/10.3389/fphar.2024.1403140
Vancouver
Henningfield JE, Grundmann O, Huestis MA, Smith KE. Kratom safety and toxicology in the public health context: research needs to better inform regulation. Frontiers in Pharmacology. 2024;15. doi:10.3389/fphar.2024.1403140
BibTeX
@article{Henningfield2024,
author = {Henningfield, Jack E and Grundmann, Oliver and Huestis, Marilyn A and Smith, Kirsten E},
title = {Kratom safety and toxicology in the public health context: research needs to better inform regulation},
journal = {Frontiers in Pharmacology},
year = {2024},
volume = {15},
doi = {10.3389/fphar.2024.1403140}
}
EUVIMED